Bisphosphonates associated osteonecrosis of the jaw: A long‐term follow‐up of a series of 35 cases observed by GISL and evaluation of its frequency over time
Open Access
- 29 September 2009
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 84 (12) , 850-852
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acidAnnals of Oncology, 2008
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Outcomes of bisphosphonate-related osteonecrosis of the jaw—Importance of staging and management guidelines: A large single institutional updateJournal of Clinical Oncology, 2008
- Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).Blood, 2007
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- Incidence of Osteonecrosis of the Jaw in Patients With Multiple Myeloma and Breast or Prostate Cancer on Intravenous Bisphosphonate TherapyJournal of Oral and Maxillofacial Surgery, 2007
- Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patientsLeukemia & Lymphoma, 2007
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003